BridgeBio Pharma (NASDAQ:BBIO) Stock Bought by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on November 2nd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

BridgeBio Pharma Stock Performance

Shares of BBIO stock traded down $1.37 during mid-day trading on Thursday, hitting $78.17. The company’s stock had a trading volume of 1,804,089 shares, compared to its average volume of 3,105,492. BridgeBio Pharma, Inc. has a 52 week low of $62.50 and a 52 week high of $93.42. The company’s fifty day simple moving average is $69.92 and its 200-day simple moving average is $72.79.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.12. The business had revenue of $353.17 million for the quarter, compared to analyst estimates of $293.47 million. During the same period in the prior year, the business earned ($0.95) EPS. The company’s revenue for the quarter was up 192.6% on a year-over-year basis. As a group, equities research analysts expect that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current year.

Insider Activity at BridgeBio Pharma

In other news, CEO Neil Kumar sold 10,000 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the transaction, the chief executive officer owned 495,686 shares of the company’s stock, valued at approximately $34,241,988.88. This represents a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the sale, the chief accounting officer owned 120,687 shares in the company, valued at $8,792,047.95. This trade represents a 1.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 56,980 shares of company stock worth $4,563,699 over the last quarter. Corporate insiders own 14.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on BBIO. Weiss Ratings cut BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. UBS Group reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Friday, October 30th. Citigroup reduced their price target on shares of BridgeBio Pharma from $94.00 to $91.00 and set a “neutral” rating for the company in a research report on Monday, October 19th. Jefferies Financial Group reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Finally, Wells Fargo & Company raised their price objective on BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Nineteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.26.

Institutional Trading of BridgeBio Pharma

A number of institutional investors have recently modified their holdings of BBIO. Jupiter Topco LLC purchased a new stake in BridgeBio Pharma during the 2nd quarter worth about $1,050,762,000. Janus Henderson Group PLC grew its stake in BridgeBio Pharma by 19.8% during the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after acquiring an additional 2,178,556 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in BridgeBio Pharma during the second quarter valued at approximately $145,663,000. Pictet Asset Management Holding SA increased its holdings in BridgeBio Pharma by 16.8% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,690,829 shares of the company’s stock worth $111,290,000 after acquiring an additional 242,703 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in BridgeBio Pharma by 1.2% in the 1st quarter. Principal Financial Group Inc. now owns 1,330,415 shares of the company’s stock worth $98,797,000 after purchasing an additional 16,112 shares in the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.